CVS Health stock hits 52-week high at 98.44 USD

CVS Health hit a 52-week high of $98.44 and has delivered a 56.6% total return over the past year, with shares up 25% in the last six months. The company remains undervalued relative to fair value, offers a 2.74% dividend yield, and has paid dividends for 56 consecutive years. CVS also plans formulary changes adding Zepbound as a preferred option in October 2026 and removing the new-to-market block on Foundayo in June 2026, while Piper Sandler reiterated an Overweight rating with a $113 target.

Analysis

CVS looks less like a momentum story and more like a rerating story with multiple legs: defensive cash flow, a still-discounted valuation, and a managed shift in formulary economics that can improve incremental gross profit without requiring heroic volume growth. The market is likely underappreciating how a pharmacy-benefit/retail platform can monetize obesity drugs not just through dispensing spread, but through higher script density, adherence, and downstream capture in adjacent categories. If the formulary changes are executed cleanly, the second-order effect is that CVS can become a preferred distribution gatekeeper at a time when demand for GLP-1s remains structurally constrained.

The main near-term risk is that enthusiasm around weight-loss access gets ahead of payer behavior. A preferred listing does not guarantee favorable utilization if plans tighten prior auth or push more aggressively toward lower-cost alternatives, and that would matter more over the next 2-3 quarters than the headline stock high. Another subtle risk is margin mix: a better formulary can increase script volume while compressing per-unit economics if rebate dynamics worsen or if competitors respond with more aggressive contracting.

The contrarian view is that the move may still be underdone if investors are pricing CVS as a mature yield name rather than a beneficiary of a multi-year channel reconfiguration in obesity treatment. The stock’s upward rerating can continue even without outsized earnings beats if management keeps de-risking the story and if the market starts assigning a higher multiple to persistent free cash flow plus capital returns. That said, the trade becomes vulnerable if the macro tape rolls over and healthcare defensiveness is rotated out in favor of higher beta cash generators.

Key Decisions for Investors

• Long CVS on pullbacks over the next 1-2 weeks; target a 10-15% upside re-rating over 3-6 months if formulary updates translate into improved mix and guidance stability. Risk is a compression back to prior valuation bands if payer pushback slows GLP-1 monetization.
• Buy CVS Jan-2027 calls and finance partially by selling higher-strike calls against the position; this expresses a multi-quarter rerating view while limiting premium outlay if the market takes longer to recognize earnings power.
• Pair trade: long CVS / short a basket of weaker pharmacy-benefit or healthcare distribution names with more exposed reimbursement sensitivity over the next 2-3 quarters. The thesis is that CVS has the best blend of cash returns and catalyst density, while laggards remain stuck in low-multiple value traps.
• For event-driven accounts, wait for confirmation in the next earnings cycle before adding size; if management raises forward commentary on specialty/GLP-1 economics, the stock can gap materially higher, but absent that, the risk/reward is better on staggered entries.